CanSino Biologics (06185.HK): PCV24 initiates Phase I/II clinical trials and completes the first subject's enrollment.

Zhitong Finance APP News, CanSino Biologics (06185.HK) announced that the company's 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin)(PCV24) has officially initiated Phase I/II clinical trials recently, and the first subject has been enrolled.